Save Product
Product Details
Application
Synonyms
MS4A1, CD20, MS4A-1
Source
Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (CD0-C52P4) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # M4ZHZ6-1).
Predicted N-terminus: Met 1
Molecular Characterization
This protein carries a GFP tag.
*The isotype control of empty/mock VLP (Cat. No. VLP-NF2P4) is sold separately and not included in protein, you can follow the link for product information.
Structure
Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.
Synthesis Process
Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.
Conjugate
GFP
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 530 nm
Formulation
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 12 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) at 10 μg/mL (100 μL/well) can bind Rituximab biosimilar (Cat. No. CD0-M36) with a linear range of 0.01-0.313 μg/mL (QC tested).
Protocol
Immobilized Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) at 5 μg/mL (100 μL/well) can bind Obinutuzumab biosimilar with a linear range of 0.3-5 ng/mL (Routinely tested).
Protocol
Immobilized Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) at 10 μg/mL (100 μL/well) can bind Ofatumumab biosimilar with a linear range of 0.005-0.078 μg/mL (Routinely tested).
Protocol
Bioactivity-FACS
2e5 of Anti-CD20 CAR-293 Cells were stained with 100 μL of 10 μg/mL of Fluorescent Cynomolgus CD20 Full Length Protein (VLP) (Cat. No. CD0-C52P4) and isotype control protein respectively. GFP signal was used to evaluate the binding activity (Routinely tested).
Protocol
Identity-DLS
The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
B-lymphocyte antigen CD20
- Category：
- Approved Drugs：
35 Details
- Drugs in Clinical Trials：
132 Details
- Highest Development Stage：
Approved
Contact Us
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
Drug Candidate Licensing
